Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEREA trial of neratinib plus endocrine therapy in HR-positive/HER2-negative HER2-enriched advanced or metastatic breast cancer
2019-000710-11Phase 2Completed
- Sponsor
- SOLTI
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of neratinib in breast cancer, sponsored by SOLTI. Primary endpoint: Progression-Free Survival at 6 months. Started Feb 2020; status: completed.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-000710-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000710-11.